$IOVA earnings report

Iovance Biotherapeutics Reports Record Third Quarter 2026 Revenue of ~$122M, Business Achievements, and Corporate Updates. AlphAI read Iovance Biotherapeutics's Third Quarter 2026 filing as strong. 2 quarters are on record below.

Third Quarter 2026

AlphAI · Earnings readIOVA · Third Quarter 2026 · ended September 30, 2026

Iovance Biotherapeutics Reports Record Third Quarter 2026 Revenue of ~$122M, Business Achievements, and Corporate Updates

✓Strong quarter

Record product revenue, higher gross margin, sharply lower net loss, and reaffirmed full-year total product revenue guidance were supported by continued U.S. Amtagvi demand.

Revenue
121,469
U.S. Amtagvi revenue
~$102 million
~77% y/y · ~12% q/q
Gross margin · other
~60%
EPS · GAAP
$ (0.05)
Full Year 2026 outlook
$410 to $420 million in total product revenue
GM Improvements in gross margin are expected to continue, excluding occasional one-time items.

Key metrics

shortened, hover for the filing’s print
MetricValueq/qy/y
Total product revenue, three months ended September 30, 2026GAAP$121.5M~22%~80%
Total revenue, three months ended September 30, 2026GAAP121,469––
Cost of sales, three months ended September 30, 2026GAAP$48.03M––
Research and development, three months ended September 30, 2026GAAP49,337decreased by ~16%–
Selling, general, and administrative, three months ended September 30, 2026GAAP38,575––
Depreciation and amortization, three months ended September 30, 2026GAAP9,497––
Restructuring charges, three months ended September 30, 2026GAAP-––
Total costs and expenses, three months ended September 30, 2026GAAP145,437––
Loss from operations, three months ended September 30, 2026GAAP(23,968)––
Interest and other income, net, three months ended September 30, 2026GAAP2,311––
Net Loss before income taxes, three months ended September 30, 2026GAAP−$21.66M––
Income tax benefit (expense), three months ended September 30, 2026GAAP(614)––
Net Loss, three months ended September 30, 2026GAAP−$22.27M––
Net Loss Per Share of Common Stock, Basic and Diluted, three months ended September 30, 2026GAAP$ (0.05)––
Weighted Average Shares of Common Stock Outstanding, Basic and Diluted, three months ended September 30, 2026GAAP455,919––
Gross margin, third quarter 2026other~60%––
Non-cash stock-based compensation included in cost of sales and operating expenses, three months ended September 30, 2026GAAP$11.83M––
Total product revenue, nine months ended September 30, 2026GAAP$292.2M––
Total revenue, nine months ended September 30, 2026GAAP292,212––
Cost of sales, nine months ended September 30, 2026GAAP$134.1M––
Research and development, nine months ended September 30, 2026GAAP170,675––
Selling, general, and administrative, nine months ended September 30, 2026GAAP116,796––
Depreciation and amortization, nine months ended September 30, 2026GAAP27,536––
Restructuring charges, nine months ended September 30, 2026GAAP-––
Total costs and expenses, nine months ended September 30, 2026GAAP449,128––
Loss from operations, nine months ended September 30, 2026GAAP(156,916)––
Interest and other income, net, nine months ended September 30, 2026GAAP6,861––
Net Loss before income taxes, nine months ended September 30, 2026GAAP−$150.1M––
Income tax benefit (expense), nine months ended September 30, 2026GAAP1,424––
Net Loss, nine months ended September 30, 2026GAAP−$148.6M––
Net Loss Per Share of Common Stock, Basic and Diluted, nine months ended September 30, 2026GAAP$ (0.34)––
Weighted Average Shares of Common Stock Outstanding, Basic and Diluted, nine months ended September 30, 2026GAAP442,683––
Non-cash stock-based compensation included in cost of sales and operating expenses, nine months ended September 30, 2026GAAP$34.84M––

Segments

SegmentRevenueq/qy/y
U.S. Amtagvi revenuecontinued U.S. Amtagvi demand~$102 million~12%~77%
Global Proleukin revenueGlobal Proleukin revenue was reported for 3Q26.~$20 million––

Amounts quoted below without a unit are in thousands, as in the filing’s tables. Per-share figures are as printed.

Full Year 2026 outlook

  • Revenue$410 to $420 million in total product revenue
  • Gross marginImprovements in gross margin are expected to continue, excluding occasional one-time items.
  • NoteAt least 110 ATCs expected to be active by the end of 2026.
  • NotePotential approval in the UK by 1Q27.
  • NotePotential MAA approval by Swissmedic expected in 1Q27.
  • NoteAn MAA for Amtagvi in advanced melanoma to ANVISA is planned in 2027.
  • NoteAn MAA resubmission for Amtagvi to the European Medicines Agency is on track for 2027.
  • NoteAn sBLA for lifileucel based on IOV-LUN-202 Cohorts 1 and 2, with a target of approximately 80 patients, is planned in 2027.
  • NotePOSI TIL ITY enrollment began this month with a target of 80 patients.
  • NoteIovance plans to initiate OP TIL ISM in 2027.
  • NoteCurrent cash is expected to fund operations well into 2029.

What drove it

  • Total product revenue was driven by continued U.S. Amtagvi demand.
  • Gross margin reflected higher Amtagvi sales volume and effective internal cost optimization programs spanning all of product production.
  • R&D expenses decreased by ~16% compared to 2Q26, driven by operational efficiencies.
  • The ATC network has grown to more than 100 U.S., Canadian, and Australian ATCs, and community ATCs represent a third of the network.
  • Amtagvi turnaround time for the majority of lots is about 30 days or less.
  • IOV-LUN-202 reported a 24.6% ORR in 69 patients with non-squamous mNSCLC, including two unconfirmed responses.
  • The biomarker-enriched subgroup within IOV-LUN-202 achieved a 59.1% ORR.
  • The confirmed ORR in UPS and DDLPS increased to 55.6% (5/9).
  • TILVANCE-301 enrollment is accelerating at more than 80 sites in the U.S., Canada, Europe, and Asia-Pacific.

Concerns

  • The company remained loss-making, with Net Loss of $ (22,271) in the third quarter and $ (148,631) for the nine months ended September 30, 2026.
  • Gross-margin improvement is expected to exclude occasional one-time items.
  • IOV-LUN-202 Cohorts 1 and 2 are completing enrollment, while independent review committee assessments, FDA discussions, and other pre-submission activities remain ongoing.
  • Clinical results may not be confirmed or reflected in independent review assessments or final analyses, according to the company’s forward-looking statements.
  • The company cited risks related to commercialization, ATC expansion, manufacturing capacity, payor coverage, revenue recognition, regulatory approvals, clinical enrollment, and potential unanticipated expenses.

What to watch

  • Achievement of the $410 to $420 million full-year 2026 total product revenue guidance range.
  • Whether gross-margin improvements continue as Amtagvi sales volume rises.
  • Expansion to at least 110 active ATCs by the end of 2026 and growth in community ATCs.
  • Completion of IOV-LUN-202 Cohorts 1 and 2 and planned 2027 sBLA preparation.
  • Enrollment in POSI TIL ITY and planned initiation of OP TIL ISM in 2027.
  • Potential UK and Switzerland approvals by 1Q27.
  • SARATOGA enrollment in UPS and DDLPS and durability of reported responses.
  • Progress of TILVANCE-301, including its early interim analysis based on ORR.

Balance sheet and cash flow

  • Cash, cash equivalents, and investments as of September 30, 2026: $ 376,320; December 31, 2025: $ 296,980.
  • Restricted cash as of September 30, 2026: $ 6,018; December 31, 2025: $ 5,980.
  • Cash position as of September 30, 2026: ~$382 million.
  • Total assets as of September 30, 2026: $ 991,214; December 31, 2025: $ 913,170.
  • Stockholders’ equity as of September 30, 2026: $ 812,662; December 31, 2025: $ 698,583.
  • Current cash is expected to fund operations well into 2029.

Analysis

Iovance reported a second consecutive record quarter, with total product revenue of $ 121,469 for the three months ended September 30, 2026, versus $ 67,455 a year earlier. The release characterized this as an increase of ~80%, with U.S. Amtagvi revenue of ~$102 million up ~77% year-over-year and ~12% from 2Q26. Global Proleukin revenue was ~$20 million. Management attributed the commercial performance to continued U.S. Amtagvi demand and said the ATC network had grown to more than 100 sites across the U.S., Canada, and Australia.

Margin and cost trends improved. Gross margin was ~60%, compared with 56% in 2Q26, reflecting higher Amtagvi volume and internal product-production cost optimization. R&D expense was 49,337 for the quarter, down from 75,174 a year earlier and described as down ~16% from 2Q26. Total costs and expenses declined to 145,437 from 162,356, reducing loss from operations to (23,968) from (94,901) and net loss to $ (22,271) from $ (91,253).

For the nine months ended September 30, 2026, total product revenue was $ 292,212, compared with $ 176,731 in the prior-year period. Despite the revenue growth and lower R&D expense, the company reported a nine-month Net Loss of $ (148,631). Balance-sheet liquidity consisted of $ 376,320 of cash, cash equivalents, and investments plus $ 6,018 of restricted cash at September 30, 2026. The company said its cash position was ~$382 million and expected current cash to fund operations well into 2029.

Management remained on track toward $410 to $420 million of full-year 2026 total product revenue and expects gross-margin improvement to continue, excluding occasional one-time items. Operational milestones include a target of at least 110 active ATCs by the end of 2026, potential UK and Swiss approvals by 1Q27, and multiple clinical programs advancing toward enrollment, regulatory engagement, or planned 2027 submissions. The principal execution items are sustaining Amtagvi demand and margin gains while advancing IOV-LUN-202, POSI TIL ITY, SARATOGA, and TILVANCE-301 through their stated clinical and regulatory milestones.

Management, verbatim

Third quarter revenue reached a new record of ~$122 million with our highest gross margin ever, driven by continued U.S. Amtagvi demand.

Frederick Vogt, Ph.D., J.D., Interim Chief Executive Officer and President

We remain on track to achieve our full-year 2026 total revenue guidance of $410 to $420 million and recently marked the tremendous milestone of more than 1,000 commercially treated Amtagvi patients.

Frederick Vogt, Ph.D., J.D., Interim Chief Executive Officer and President

Not in the filing

stated, not guessed
  • Prior full-year outlook was not provided; therefore, comparison of actual results with prior guidance is unavailable.
  • Operating cash flow was not reported.
  • Free cash flow was not reported.
  • Debt was not reported.
  • Share repurchases were not reported.
  • Dividends were not reported.
  • Non-GAAP net income or loss was not reported.
  • Non-GAAP EPS was not reported.
  • A GAAP gross-margin figure was not reported.
  • Guidance for operating expenses and tax rate was not reported.

Written by an AI language model from the company’s SEC earnings filing (Form 8-K Item 2.02, or Form 6-K for a foreign private issuer). Every figure is checked against the filing text, and a metric the filing does not print, or whose value, prior period and change do not add up, is dropped from the metrics. The model can still misread a table, in the metrics or in the text, so check a number in the filing before you rely on it. Consensus estimates, price targets and share-price reactions are not shown because they are not in the filing. AI-generated research, not investment advice.

second quarter 2026

AlphAI · Earnings readIOVA · second quarter 2026 · ended June 30, 2026

Iovance Biotherapeutics Reports Record Second Quarter 2026 Revenue of ~$99M, Business Achievements, and Corporate Updates

✓Strong quarter

Record revenue, 66% year-over-year total product revenue growth, a 56% gross margin, and continued U.S. Amtagvi demand supported a review of FY26 revenue guidance.

Revenue
$99.3M
U.S. Amtagvi revenue
~$91 million
Gross margin · other
56%
FY26 outlook
$350 million to $370 million, under review
GM Improvements in gross margin are expected to continue, excluding occasional one-time items.

Key metrics

shortened, hover for the filing’s print
MetricValueq/qy/y
Revenueother$99.3M––
Total product revenueother~$99 million39%66%
Gross marginother56%––
Research and Development (R&D) expensesotherdecreased by ~6%decreased by ~6%–
Cash positionother~$304 million––

Segments

SegmentRevenueq/qy/y
U.S. Amtagvi revenueContinued U.S. Amtagvi demand, supported by a new marketing campaign and an expanded sales team, drove increased adoption across a growing ATC network and referrals toward earlier treatment.~$91 million––
Global Proleukin revenueGlobal Proleukin revenue is expected to grow during the remainder of 2026.~$9 million––

FY26 outlook

  • Revenue$350 million to $370 million, under review
  • Gross marginImprovements in gross margin are expected to continue, excluding occasional one-time items.
  • NoteAn update to FY26 total revenue guidance will be provided during the third quarter.
  • NoteCurrent cash is expected to fund operations into 2H28.
  • NoteAt least 110 ATCs are expected to be active by the end of 2026.
  • NotePotential approval of the MAA in Switzerland is expected in 1H27.
  • NoteProgram updates for IOV-LUN-202 are expected in 4Q26.
  • NoteA supplemental Biologics License Application (sBLA) submission for IOV-LUN-202 is planned in 2027.
  • NoteInitial data from investigator-sponsored trials in CSCC and MCC are expected in 1H27.

What drove it

  • Total product revenue increased 66% from 2Q25 and 39% from 1Q26.
  • Gross margin reflected higher Amtagvi sales volume, continued cost optimization, and maturing internal manufacturing efficiencies.
  • R&D expenses decreased by ~6% compared to 1Q26, driven by continued operational efficiencies during the fourth straight quarter of improvements.
  • Record Amtagvi demand was catalyzed by a new marketing campaign and an expanded sales team.
  • The authorized treatment center network has grown to more than 95 U.S., Canadian, and Australian ATCs.
  • Unaided physician awareness of Amtagvi has nearly tripled during the last year.
  • Amtagvi turnaround time is 31 days or less using the centralized commercial manufacturing process approved by FDA for TIL therapy.

Concerns

  • FY26 total revenue guidance of $350 million to $370 million is under review rather than updated in this release.
  • Gross-margin improvement guidance excludes occasional one-time items.
  • The U.K. MAA was resubmitted in early July and remains under expedited MHRA review for potential approval later in 2026.
  • The European Medicines Agency MAA resubmission for Amtagvi in advanced melanoma is on track for 2027.
  • Several pipeline programs remain in enrollment, early clinical development, or registrational studies.

What to watch

  • The third-quarter update on FY26 total revenue guidance.
  • Whether gross-margin improvements continue as expected, excluding occasional one-time items.
  • Progress toward at least 110 active ATCs by the end of 2026 and growth in community ATCs.
  • Potential U.K. Amtagvi approval later in 2026 and the expected Swiss MAA decision in 1H27.
  • IOV-LUN-202 program updates expected in 4Q26 and the planned 2027 sBLA submission.
  • SARATOGA results scheduled for an oral presentation at ESMO in Madrid, Spain, from October 23–27, 2026.
  • Initial investigator-sponsored trial data in CSCC and MCC expected in 1H27.

Balance sheet and cash flow

  • As of June 30, 2026, Iovance’s cash position was ~$304 million.
  • Cash, cash equivalents, short-term investments, and restricted cash as of June 30, 2026.
  • Current cash is expected to fund operations into 2H28.

Analysis

Iovance reported record second-quarter revenue of $99.3 million. Total product revenue was reported at approximately $99 million, up 66% from approximately $60 million in 2Q25 and 39% from approximately $71 million in 1Q26. U.S. Amtagvi revenue was approximately $91 million, while Global Proleukin revenue was approximately $9 million. The release attributes the result to continued U.S. Amtagvi demand, increased awareness, a new marketing campaign, an expanded sales team, and greater adoption across the authorized treatment center network.

Margin execution improved alongside revenue growth. Gross margin was 56%, excluding depreciation and amortization, reflecting higher Amtagvi sales volume, cost optimization, and maturing internal manufacturing efficiencies. R&D expenses decreased by approximately 6% compared with 1Q26, which management described as the fourth straight quarter of improvements. The reported combination of higher revenue, improving gross margin, and lower sequential R&D expense points to continued operating-efficiency progress.

Commercial infrastructure continues to expand. The ATC network exceeded 95 U.S., Canadian, and Australian centers, with community ATCs representing a third of the network. Iovance expects at least 110 ATCs to be active by the end of 2026. Internationally, the Australian marketing authorization application was approved, the U.K. application was resubmitted in early July under expedited review, and a Swiss decision is expected in 1H27. These regulatory and network developments are central to the next phase of Amtagvi access expansion.

Management is reviewing its FY26 total revenue guidance of $350 million to $370 million based on second-quarter sales and current demand trends, but did not issue a revised range in this release. It expects gross-margin improvements to continue, excluding occasional one-time items. The company reported a cash position of approximately $304 million as of June 30, 2026, consisting of cash, cash equivalents, short-term investments, and restricted cash, and stated that current cash is expected to fund operations into 2H28.

The clinical pipeline added regulatory and development milestones. FDA Fast Track Designation was granted for lifileucel in soft tissue sarcomas, while IOV-LUN-202 enrollment is nearly complete in pivotal cohorts and program updates are expected in 4Q26. The key near-term operating issues are the third-quarter revenue-guidance update, sustained gross-margin improvement, ATC activation, international regulatory progress, and forthcoming pipeline data and program updates.

Management, verbatim

Second-quarter revenue reached a record $99.3 million with gross margin of 56%, driven by continued U.S. Amtagvi demand,

Frederick Vogt, Ph.D., J.D., Interim President and Chief Executive Officer

Not in the filing

stated, not guessed
  • GAAP gross profit, operating income or loss, net income or loss, and diluted EPS were not provided in the supplied filing text.
  • Non-GAAP operating income or loss, net income or loss, and EPS were not provided in the supplied filing text.
  • Prior-year and prior-quarter gross margin were not provided.
  • Amtagvi prior-year revenue and prior-quarter revenue were not provided. The release states Amtagvi revenue was up 40% from 4Q25, but does not provide the corresponding revenue amount.
  • Operating cash flow and free cash flow were not provided.
  • Debt was not provided.
  • Share repurchases, dividends, and other capital-return amounts were not provided.
  • FY26 operating-expense guidance and tax-rate guidance were not provided.
  • A revised FY26 revenue-guidance range was not provided.
  • A previous outlook section was not provided; therefore, no reported-versus-prior-guidance comparison is included.

Written by an AI language model from the company’s SEC earnings filing (Form 8-K Item 2.02, or Form 6-K for a foreign private issuer). Every figure is checked against the filing text, and a metric the filing does not print, or whose value, prior period and change do not add up, is dropped from the metrics. The model can still misread a table, in the metrics or in the text, so check a number in the filing before you rely on it. Consensus estimates, price targets and share-price reactions are not shown because they are not in the filing. AI-generated research, not investment advice.

Questions about IOVA earnings dates

When is Iovance Biotherapeutics's next earnings date?
AlphAI has no date for IOVA yet. We do not publish estimates, so this page shows a date the day we have one.
Why is there sometimes no date?
AlphAI leaves out estimates. Many sites fill the gap by adding about 91 days to the last report, but that arithmetic is a guess, and a wrong date costs a reader more than a missing one, so we show nothing until a date is set, and a company can still move it. Every quarter already on this page is read straight from the SEC filing: an 8-K item 2.02 for US filers, a 6-K earnings release for foreign private issuers.